Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on Rigel Pharmaceuticals’ receptor-interacting serine/threonine-protein kinase 1 ...

Rigel Pharmaceuticals (RIGL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

Rigel Pharmaceuticals (RIGL) caught the market’s eye after reporting record sales for the third quarter, strong annual growth in revenue and net income, and raising its 2025 revenue forecast above ...

Rigel's Q2 results were outstanding, with revenue nearly doubling and net income surging, driven by strong commercial momentum for TAVALISSE, GAVRETO, and REZLIDHIA. Management raised 2025 guidance, ...

Rigel Pharmaceuticals reported a strong third quarter for 2025, with revenue reaching 69.5 million dollars, a significant increase compared to the previous year. Despite this growth, the company’s ...